Yanet Borrego, deputy director-general and representative of the joint venture Biotech Pharma (BPL), told Prensa Latina the decision by the National Administration of Medicines has endorsed the results of working years in clinical trials to extend Nimotuzumab application.

Borrego recalled that Nimotuzumab had been approved in China since 2008 as part of a treatment against nasopharyngeal cancer. It has been administered to some 200,000 patients.

Nowadays, Nimotuzumab registration will allow to open up more ground in China, which has a 25% worldwide incidence of pancreatic cancer, and over 120,000 cases diagnosed each year.

Meanwhile, Borrego stressed the clinical trials have found a survival rate of over a year and the antiviral was well tolerated in combination with Gemcitabine.

pll/omr/mgt/ymr